Alteogen Inc.

The South Korea government plans to improve the transparency and objectivity of standards for pharma firms to officially qualify as “innovative” and eligible for special policy treatment, amid foreign

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Dr. Reddy’s Acquires Rights From

Merck & Co. is awaiting regulatory approvals for its subcutaneous version of PD-1 inhibitor pembrolizumab, and its successful head-to-head trial against the original intravenous Keytruda (pembroli

Sentiment around initial public offerings (IPOs) appears to be slowly recovering in South Korea as the market stabilizes somewhat amid ongoing political uncertainties at home and abroad. A couple of b